Cytosorbents CORP

CytoSorbents Corporation received a notice from Nasdaq indicating non-compliance with minimum market value requirements, with 180 days to regain compliance.

CytoSorbents has scheduled two August 2026 FDA pre-submission meetings to advance its DrugSorb-ATR regulatory strategy.

CytoSorbents Corporation announced its first quarter 2026 financial results, showing a slight revenue increase but a wider net loss, while also providing updates on its DrugSorb-ATR regulatory pathway.

CytoSorbents Corporation announced its full year and fourth quarter 2025 financial results, showing modest revenue growth, improved GAAP net loss, but worsening adjusted net loss, alongside strategic restructuring and ongoing FDA discussions for DrugSorb-ATR.

CytoSorbents Corporation announced third quarter 2025 financial results, reporting 10% revenue growth, an amended credit agreement, and a workforce reduction plan aimed at achieving cash-flow breakeven by Q1 2026.

CytoSorbents Corporation received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, risking its listing.

CytoSorbents Corporation reported a significantly reduced net loss for the nine months ended September 30, 2025, driven by revenue growth and cost reductions, despite regulatory setbacks for DrugSorb-ATR and Nasdaq compliance concerns.

CytoSorbents Corporation reports increased revenue and improved operating loss in Q2 2025, but faces significant regulatory setbacks for DrugSorb-ATR in the U.S. and Canada, raising going concern doubts.

CytoSorbents' Q1 2025 revenue dipped slightly, but the company is optimistic about future growth following strategic changes and potential regulatory approvals.

CytoSorbents Corporation saw a revenue increase in Q3 2024, while also experiencing a reduction in net losses compared to the same period last year.

CytoSorbents Corporation announced its second quarter 2024 financial results, highlighted by a new $20 million debt facility and progress in clinical trials.

CytoSorbents Corporation announced its first quarter 2024 financial results, highlighting a revenue increase in product sales and progress in clinical trials, while also noting ongoing financial challenges.

CytoSorbents Corporation has filed an amendment to its 2025 Form 10-K, primarily to include Part III disclosures and updated executive certifications.

CytoSorbents grew 2025 revenue 4% and improved margins but flagged going concern risks, Nasdaq noncompliance, and a reset FDA path for DrugSorb-ATR after a 2025 De Novo denial.

CytoSorbents Corporation files its 2024 10-K, highlighting revenue growth, reduced operating losses, and progress towards regulatory approval for DrugSorb-ATR.

CytoSorbents Corporation's 2023 annual report highlights a year of strategic advancements, including progress in clinical trials and regulatory submissions, alongside ongoing commercialization efforts.

Cytosorbents Corp. Chief Financial Officer Peter J. Mariani acquired 100,000 shares of common stock through an open market purchase.

CytoSorbents Corporation CEO Phillip P. Chan acquired 261,469 shares of common stock through open market purchases.

Cytosorbents Corporation's CEO, Phillip P. Chan, purchased 100,000 shares of common stock in an open market transaction.

Cytosorbents Corporation's CEO, Phillip P. Chan, was granted 105,600 restricted stock units and 136,400 stock options as part of his compensation.

Cytosorbents Director Edward R. Jones acquired 22,000 stock options and holds 88,834 common shares and RSUs, as detailed in a recent SEC filing.

Cytosorbents Corporation Director Michael G. Bator reported the grant of 44,000 stock options and updated his beneficial ownership of common stock and restricted stock units.

CytoSorbents Corporation has scheduled its 2026 Annual Meeting for August 13, 2026, to vote on director elections, executive compensation, and a proposed reverse stock split.

Cytosorbents Corporation has filed a definitive proxy statement with the SEC.

CytoSorbents Corporation will hold its annual meeting of stockholders virtually on June 12, 2025, to vote on director elections, executive compensation, and auditor ratification.

CytoSorbents Corporation announces its 2024 Annual Meeting to be held virtually on June 6, 2024, with stockholders voting on director elections, executive compensation, an incentive plan amendment, and auditor ratification.

CytoSorbents Corporation will hold its annual meeting of stockholders virtually on June 6, 2024, to vote on director elections, executive compensation, an amendment to the long-term incentive plan, and ratification of the independent accounting firm.

Avenir Corporation and James H. Rooney have reported a beneficial ownership of 8.33% in Cytosorbents Corp's common stock.

Avenue Venture Opportunities Funds and related entities have disclosed a combined beneficial ownership of 5.7% in Cytosorbents Corp, primarily through convertible loans and warrants.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 3.11% beneficial ownership stake in CytoSorbents Corp as of March 31, 2025.

Skylands Capital, LLC has disclosed a passive beneficial ownership of 4.8% of CytoSorbents Corporation's common stock as of March 31, 2025.

Avenir Corporation and James H. Rooney have disclosed a shared beneficial ownership of 5.66% of Cytosorbents Corp's common stock as of December 31, 2024.

The Vanguard Group has reported a 7.13% passive beneficial ownership stake in CytoSorbents Corp's common stock as of December 31, 2024.